NEWARK, Del, April 06, 2023 (GLOBE NEWSWIRE) -- The triptorelin market is expected to be worth around US$ 955.50 million in 2023. The industry is predicted to expand at a 5% CAGR from 2023 to 2033, powered by the rising prevalence of endometriosis among females worldwide. By 2033, the triptorelin market is expected to generate US$ 1556.41 million.
Dynamics of the Market
Due to increased rates of central precocious puberty, salivary gland cancer, and prostate cancer in young individuals under the age of eight and nine are recorded. Throughout the forecast period, there are bound to be numerous opportunities for the triptorelin industry to flourish.
Get a holistic overview of the market from industry experts to evaluate and develop growth strategies. Download the sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16936
A rise in the frequency of different endocrine illnesses increasing knowledge of various choices for therapy expanding numerous medical facilities and pharmacies. As the frequency of numerous endocrine disorders is rising; people are becoming aware of their treatment options. There are many hospitals and pharmacies in the market, which are the main drivers boosting the triptorelin industry.
Initiatives by the government to raise awareness about endocrine problems are boosting market expansion. But the triptorelin market expansion is anticipated to be constrained by the high cost of triptorelin therapy and its adverse effects.
- Triptodur (triptorelin), a medication used to treat children with Central Precocious Puberty, became commercially accessible in the United States in October 2017 thanks to Arbor Pharmaceuticals, LLC and Debiopharm International SA.
- Triptorelin 22.5 mg can be marketed and sold in the United States for treating central precocious puberty, both businesses stated in January 2016.
Strong Points
|
Restraints
|
Opportunities
|
Challenges
|
For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2033, Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16936
Regional Outlook
North America - The increased incidence of prostate cancer and rising demand for hormone therapy among men are both factors contributing to the expansion of the triptorelin industry in North America. This factor also allows the United States to get the lion's share of North America triptorelin sales in 2033.
Latin America - The two countries that are likely to contribute the most to regional earnings are Brazil and Mexico. Growing government programmes for cancer awareness and early diagnosis as well as rising healthcare costs are some of the causes that can be linked to the increase in this area.
Europe - The principal sources of income in this region are anticipated to be Germany and France. Increased government programmes for cancer awareness and early diagnosis, andas increased healthcare costs are some of the factors contributing to this region's growth.
Asia Pacific and the Middle East & Africa - The frequency of numerous endocrine problems is on the rise,. People are becoming more aware of the available treatment choices, which can be ascribed to the increase in Asia Pacific and Middle East & Africa. In these areas, the triptorelin demand is being fueled by the expansion of hospitals and pharmacies.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16936
Key Takeaways
- From 2023 to 2033, the triptorelin market share from the triptorelin embonate segment is expected to increase by more than 5% CAGR.
- Due to the rising incidence of cancer, the cancer category accounted for more than 25% of the total triptorelin industry share in 2023.
- Triptorelin market share from the intradermal sector is expected to increase at a CAGR of about 4.5% from 2023 to 2033, according to the route of administration.
- By 2033, Europe market is expected to be worth USD 370 million.
Environment of Competitiveness
LGM Pharma, Ipsen Pharma, BACHEM, Ferring B.V., Merck & Co., Inc., Taj Pharmaceuticals Ltd, Varian Pharmed, Verity Pharmaceuticals Inc., and Dr. Reddy's Laboratories Ltd. are a few well-known triptorelin manufacturers. To increase their influence in the market, many triptorelin businesses place a strong emphasis on partnerships and collaborations.
Novel Innovations and Advancements
- Partnership
- To commercialise many of Amneal's sophisticated generic drugs, the American pharmaceutical company Amneal Pharmaceuticals announced in January 2023 that it had entered into a long-term partnership arrangement with the Finnish pharmaceutical business Orion Corporation.
- Orion to broadcast the complicated generic programmes of the Company throughout New Zealand, Australia, and much of Europe as a result of this deal. It is going to aid the business in bolstering its product line in Europe.
Key Segments
Global Triptorelin Industry By Drug Type:
- Triptorelin Pamoate
- Triptorelin Acetate
- Triptorelin Embonate
Global Triptorelin Industry By Application:
- Prostate Cancer
- Radical Prostatectomy
- Endometriosis
- Salivary Gland Cancer
- Central Precocious Puberty
Global Triptorelin Industry By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Table of Content
1. Executive Summary | Triptorelin Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Explore FMI’s Extensive Coverage On Healthcare Domain:
Antimycotics Market Size: It has been noted that the prevalence of fungus infections has dramatically increased during the last 20 years. Patients with cancer, AIDS patients, and transplant recipients are more likely to experience these situations.
Motion Preservation Devices Market Demand: By 2032, the market for motion preservation devices will be worth US$ 3.0 million, up from US$ 1.7 million in 2022, and will have grown at a CAGR of 5.3%.
Assisted Walking Devices Market Share: The forecast term is expected to see a moderately paced CAGR of 6.4% for the global market for assisted walking devices. In 2022, the market is expected to be worth US$3.62 billion.
Adiponectin Testing Market Opportunity: Over the forecast period of 2022–2032, the adiponectin testing market is anticipated to deepen its roots in the worldwide market at a CAGR of 7.9%. The market is valued at US$ 45.11 billion in 2022, and by 2032, it's predicted to reach US$ 89 billion.
Intracranial Aneurysm Market Growth: The global market for intracranial aneurysms is anticipated to grow at a promising CAGR of 8.8% between 2022 and 2032. The market is expected to reach USD 2.56 billion by 2032, up from its USD 1.2 billion market value in 2022.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn | Twitter | Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
